(firstQuint)Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis.

 Icotinib Hydrochloride is a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which has been approved for the treatment of advanced nonsmall- cell lung cancer (NSCLC) in China in its oral form.

 As EGFR is implicated in the pathogenesis of psoriasis, icotinib hydrochloride is being developed as a cream for the treatment of mild to moderate psoriasis.

 This is a single-center, randomized, doubleblind, placebo-controlled study of 0.

5%, 1.

0%, 2.

0%, 4.

0% icotinib hydrochloride cream by topical administration.

 Icotinib hydrochloride cream will be applied to subjects with mild to moderate psoriasis.

 Approximately 40 subjects will be enrolled.

.

 Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis@highlight

This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.

